Table of Content

1 INTRODUCTION 
    1.1 OBJECTIVES OF THE STUDY  
    1.2 MARKET DEFINITION  
           1.2.1 KEY INCLUSIONS & EXCLUSIONS 
    1.3 RESEARCH SCOPE  
           1.3.1 SEGMENTS COVERED 
           1.3.2 GEOGRAPHIC SCOPE 
           1.3.3 YEARS CONSIDERED FOR THE STUDY 
    1.4 CURRENCY USED FOR THE STUDY  
    1.5 MAJOR MARKET STAKEHOLDERS  
    1.6 SUMMARY OF CHANGES  
           1.3.3 RECESSION IMPACT 
2 RESEARCH METHODOLOGY  
    2.1 RESEARCH DATA SOURCES 
           2.1.1 SECONDARY DATA 
           2.1.2 PRIMARY DATA
    2.2 MARKET SIZE ESTIMATION METHODOLOGY   
    2.3 MARKET SHARE ESTIMATION METHODOLOGY  
    2.4 MARKET BREAK DOWN AND DATA TRIANGULATION   
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RESEARCH LIMITATIONS   
           2.6.1 SCOPE RELATED LIMITATIONS 
           2.6.2 METHODOLOGY RELATED LIMITATIONS
    2.7 RISK ASSESSMENT  
    2.8 RECESSION IMPACT ASSESSMENT APPROACH   
3 EXECUTIVE SUMMARY  
4 PREMIUM INSIGHTS  
    4.1 DIAGNOSTIC ECG  MARKET: MARKET OVERVIEW  
    4.1 DIAGNOSTIC ECG  MARKET, BY PRODUCT   
    4.1 GEOGRAPHIC ANALYSIS: DIAGNOSTIC ECG  MARKET  MARKET, BY COUNTRY AND REGION  
    4.1 GEOGRAPHIC SNAPSHOT OF THE DIAGNOSTIC ECG  MARKET  MARKET  
5 MARKET OVERVIEW  
    5.1 MARKET DYNAMICS  
           5.1.1 MAJOR DRIVERS 
           5.1.2 KEY RESTRAINTS
           5.1.3 KEY GROWTH OPPORTUNITIES 
           5.1.4 INDUSTRY-SPECIFIC CHALLENGES 
    5.2 REGULATORY LANDSCAPE 
           5.2.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
           5.2.2 REGULATORY ANALYSIS
    5.3 VALUE CHAIN ANALYSIS 
    5.4 SUPPLY CHAIN ANALYSIS 
    5.5 ECOSYSTEMS LANDSCAPE 
    5.6 TECHNOLOGY ANALYSIS 
    5.7 TRADE DATA ANALYSIS 
    5.8 PATENT ANALYSIS 
    5.9 PORTER’S FIVE FORCE ANALYSIS 
    5.10 PRICING ANALYSIS 
           5.10.1 AVERAGE SELLING PRICE OF KEY PLAYERS BY PRODUCT
           5.10.2 AVERAGE SELLING PRICE TRENDS
    5.11 KEY CONFERENCES AND EVENTS IN 2022-23 
    5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.12.1 KEY STAKEHOLDERS AND BUYING CRITERIA
           5.12.2 BUYING CRITERIA
    5.13 REIMBURSEMENT SCENARIO 
6 DIAGNOSTIC ECG  MARKET, BY PRODUCT TYPE (USD MILLION; 2021—2028)*  
    6.1 DEVICES 
           5.12.1 RESTING ECG DEVICES
           5.12.1 STRESS ECG DEVICES
           5.12.1 IMPLANTABLE LOOP RECORDERS
           5.12.1 MOBILE CARDIAC TELEMETRY DEVICES (MCT)
           5.12.1 EVENT MONITORS
           5.12.1 HOLTER MONITORS
           5.12.1 SMART ECG MONITORS
    6.2 SOFWARE AND SERVICES 
7 DIAGNOSTIC ECG  MARKET, BY LEAD TYPE  (USD MILLION; 2021—2028)*  
    7.1 12-LEAD 
    7.2 5-LEAD 
    7.3 3-LEAD 
    7.3 6-LEAD 
    7.3 SINGLE-LEAD 
    7.3 OTHER LEAD TYPES 
8 DIAGNOSTIC ECG  MARKET, BY END-USER (USD MILLION; 2021—2028)*  
    8.1 HOSPITALS, CLINICS AND CARDIAC CENTERS 
    8.2 AMBULATORY SURGICAL  CENTERS  
    8.3 OTHER END USERS 
9 DIAGNOSTIC ECG  MARKET, BY REGION (USD MILLION; 2021—2028)*  
    9.1 NORTH AMERICA 
           9.1.1 RECESSION IMPACT
           9.1.2 US
           9.1.3 CANADA
    9.2 EUROPE  
           9.2.1 RECESSION IMPACT
           9.2.2 GERMANY
           9.2.3 UK
           9.2.4 FRANCE
           9.2.5 ITALY 
           9.2.6 SPAIN 
           9.2.7 REST OF EUROPE
    9.3 ASIA-PACIFIC 
           9.3.1 RECESSION IMPACT 
           9.3.2 JAPAN 
           9.3.3 CHINA 
           9.3.4 INDIA 
           9.3.5 SOUTH KOREA 
           9.3.6 AUSTRALIA 
           9.3.7 REST OF ASIA-PACIFIC
    9.4 LATIN AMERICA 
           9.4.1 RECESSION IMPACT
           9.4.2 BRAZIL
           9.4.3 MEXICO
           9.4.4 REST OF LATIN AMERICA 
    9.5 MIDDLE EAST AND AFRICA  
10 RECESSION IMPACT
11  COMPETITIVE LANDSCAPE  
     11.1 OVERVIEW  
     11.2 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022)  
     11.3 MARKET SHARE ANALYSIS FOR TOP 5 GLOBAL PLAYERS (IN TERMS OF %REVENUE, IN 2022)  
     11.4 COMPANY FOOTPRINT ANALYSIS  
     11.5 COMPETITIVE BENCHMARKING 
     11.6 COMPETITIVE SITUATION AND TRENDS (2021-2023)  
             11.6.1 PRODUCT LAUNCHES
             11.6.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
             11.6.2 PRODUCT APPROVALS
             11.6.2 ACQUISITIONS
     11.7 COMPANY EVALUATION QUADRANT  
             11.7.1 PERVASIVE PLAYERS
             11.7.2 EMERGING LEADERS
             11.7.3 PARTICIPANTS
             11.7.4 STARS
     11.8 SME/START-UP EVALUATION QUADRANT  
             11.8.1 PROGRESSIVE COMPANIES
             11.8.2 RESPONSIVE COMPANIES
             11.8.3 DYNAMIC COMPANIES
             11.8.4 STARTING BLOCKS
12 COMPANY PROFILES** 
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
     12.1 MAJOR PLAYERS  
             12.1.1 GE HEALTHCARE
             12.1.2 KONINKLIJKE PHILIPS N.V.
             12.1.3 NIHON KOHDEN CORPORATION
             12.1.4 HILL-ROM HOLDINGS, INC.
             12.1.5 AMBU A/S
             12.1.6 SCHILLER AG
             12.1.7 ACS DIAGNOSTICS
             12.1.8 BPL MEDICAL TECHNOLOGIES
             12.1.9 FUKUDA DENSHI
             12.1.9 BIOTELEMETRY, INC.
             12.1.11 OSI SYSTEMS, INC.
             12.1.12 BTL
             12.1.13 ALLENGERS MEDICAL SYSTEMS, LTD. 
     12.2 OTHER PLAYERS  
             12.2.1 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS
             12.2.2 EDAN INSTRUMENTS, INC.
             12.2.3 CARDIOLINE SPA
             12.2.4 NORAV MEDICAL
             12.2.5 BIONET CO., INC.
             12.2.6 VECTRACOR, INC.
             12.2.7 INNOMED MEDICAL
             12.2.8 ECCOSUR
             12.2.9 SUZUKEN CO. LTD
             12.2.10 NEXUS LIFECARE
             12.2.11 ACCURKARDIA
             12.2.12 IDOVEN AI
             12.2.13 CARDIOMATICS
             12.2.14 CARDIACARE
             12.2.15 PEERBRIDGE HEALTH
             12.2.16 MIDMARK CORPORATION
13 APPENDIX 
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 AVAILABLE CUSTOMIZATIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS